Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration

Trial Profile

Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Oct 2016 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 19 Oct 2016 Planned primary completion date changed from 1 Apr 2018 to 1 Mar 2019.
    • 06 Apr 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Apr 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top